ING Groep NV lessened its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 13.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,722 shares of the biotechnology company’s stock after selling 728 shares during the quarter. ING Groep NV’s holdings in BioMarin Pharmaceutical were worth $421,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently made changes to their positions in the company. Rothschild Investment Corp IL purchased a new stake in shares of BioMarin Pharmaceutical during the fourth quarter worth about $657,000. Schwab Charles Investment Management Inc. boosted its holdings in shares of BioMarin Pharmaceutical by 7.5% during the third quarter. Schwab Charles Investment Management Inc. now owns 320,485 shares of the biotechnology company’s stock worth $29,828,000 after purchasing an additional 22,242 shares during the period. Swiss National Bank boosted its holdings in shares of BioMarin Pharmaceutical by 1.8% during the third quarter. Swiss National Bank now owns 643,200 shares of the biotechnology company’s stock worth $59,863,000 after purchasing an additional 11,600 shares during the period. Dupont Capital Management Corp boosted its holdings in shares of BioMarin Pharmaceutical by 209.3% during the third quarter. Dupont Capital Management Corp now owns 5,763 shares of the biotechnology company’s stock worth $536,000 after purchasing an additional 3,900 shares during the period. Finally, KBC Group NV lifted its holdings in BioMarin Pharmaceutical by 8.7% in the third quarter. KBC Group NV now owns 366,872 shares of the biotechnology company’s stock worth $34,145,000 after buying an additional 29,264 shares during the period.
BMRN has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $101.00 price objective for the company in a report on Tuesday, January 16th. Piper Jaffray Companies restated a “buy” rating and issued a $114.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, January 18th. SunTrust Banks lifted their target price on shares of BioMarin Pharmaceutical to $130.00 and gave the company a “buy” rating in a report on Monday, December 11th. JPMorgan Chase & Co. set a $131.00 target price on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a report on Monday, November 27th. Finally, Deutsche Bank set a $124.00 target price on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a report on Friday, February 23rd. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $112.34.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at $86.16 on Wednesday. BioMarin Pharmaceutical Inc. has a one year low of $77.04 and a one year high of $100.51. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.12 and a current ratio of 2.70.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.06). The company had revenue of $358.31 million during the quarter, compared to analysts’ expectations of $346.24 million. BioMarin Pharmaceutical had a negative return on equity of 3.18% and a negative net margin of 8.91%. research analysts forecast that BioMarin Pharmaceutical Inc. will post -0.67 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “ING Groep NV Lowers Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)” was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://weekherald.com/2018/03/14/ing-groep-nv-decreases-position-in-biomarin-pharmaceutical-inc-bmrn.html.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.